论文部分内容阅读
通过５０％ＰＥＧ诱导细胞融合，ＨＡＴ选择培养得到Ｂ１６黑色素瘤与活化Ｂ淋巴细胞的融合细胞（Ｂ１６．Ｂ）。体外进行混合淋巴细胞、肿瘤细胞培养，发现Ｂ１６．Ｂ能诱发小鼠脾脏淋巴细胞的增生反应，而Ｂ１６无此作用。体内实验表明：Ｂ１６．Ｂ３次免疫后，能获得对Ｂ１６攻击的抵抗，皮下形成肿瘤时间较Ｂ１６免疫组明显推迟，存活期也延长，但不能获得对无关瘤株的抵抗力。对荷瘤小鼠的治疗实验也显示，Ｂ１６．Ｂ腹腔注射能够明显抑制肿瘤生长，延长动物存活期。
The cell fusion was induced by 50% PEG and HAT was selected for culture to obtain B16 melanoma and activated B lymphocyte fused cells (B16.B). In vitro mixed lymphocyte, tumor cell culture, found B16. B can induce splenic lymphocyte proliferation in mice, but B16 did not. In vivo experiments showed: B16. After B3 immunization, resistance to B16 challenge was obtained. Subcutaneous tumor formation time was significantly delayed compared with the B16 immunization group, and the survival period was also prolonged, but resistance to an unrelated tumor strain could not be obtained. Treatment experiments on tumor-bearing mice also showed that B16. B intraperitoneal injection can significantly inhibit tumor growth and prolong animal survival.